Jeroen Wissink, CEO of U-Needle, will attend the ATTD 2019 meeting in Berlin, Germany on February 20-23. Please send us an email if you would like to meet up and learn more about U-Needle's insulin infusion developments for diabetes therapy and our ambitions.
U-Needle develops proprietary hollow-microneedle technology applied in various user-friendly intradermal injection/infusion devices for vaccination, immunotherapy, diabetes and aesthetics. Perpendicular needle insertion with our short silicon microneedles provides full control of injection depth and reduced needle fear / pain for the patient.
For diabetic glycemic control we are developing an intradermal infusion set. Intradermal insulin delivery facilitates fast therapy onset and reduced dose.
Please visite our website for further information on U-Needle.